VEGFA and neoplasm: To address these limitations, combination therapies incorporating agents that inhibit the VEGF pathway (e.g., bevacizumab) which promotes tumor angiogenesis, have been developed to enhance the activity of ICIs (e.g., atezolizumab) and demonstrated improved clinical response (5, 51, 59).